FindMyKOL

Ellie Kelepouris, MD

Basic profile

University of Pennsylvania

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionPhiladelphia, PA · NortheastSpecialtyNephrologyFocusNephrology
Active KOLFindMyKOL type: NationalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Ellie Kelepouris is a Nephrology physician affiliated with University of Pennsylvania. OpenAlex indexes 63 publications with 10,187 citations (h-index 18). By OpenAlex citation count, this profile ranks in the top 10% of Nephrology profiles in the FindMyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
63publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

10,187citations

Citations across these publications.

18h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
25companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Calliditas Therapeutics US Inc.
    Program year202522 payments
    $23,619
  • AKEBIA THERAPEUTICS INC
    Program year202523 payments
    $11,343
  • Vifor (International) Ltd.
    Program year20252 payments
    $10,433
All 48 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    56.8%
    Calcium channel blocker15.7%
    Amlodipine Besylate73%Nifedipine Er28%
    Part D<11 patients
    Loop diuretic10%
    Furosemide61%Bumetanide39%
    Part D<11 patients

    + 7 more classes in this area

  • Metabolism & gastrointestinal

    14.7%
    Metabolic Alkalinizer4.5%
    Potassium Citrate Er100%
    Part D<11 patients
    Vitamin D3 Analog3.3%
    Calcitriol100%
    Part D<11 patients

    + 3 more classes in this area

  • Blood & clotting

    8.6%
    Solutions for parenteral nutrition8.6%
    Calcium Acetate100%
    Part D≥14 patients
Where care is delivered (Part B)58.5% facility · 41.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”